Pharmaceutical

Arialief Supplement: Vitamins Reviews and Complaints for Neuropathic Pain

HONOLULU, April 09, 2025 (GLOBE NEWSWIRE) -- Arialief is a premium dietary supplement specifically designed to target the root causes…

9 months ago

Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in…

9 months ago

PetMed Express, Inc. Announces Appointment of Peter Batushansky to Board of Directors

Former pet industry executive with more than 20 years of experience across retail, pet, healthcare, and private equity Third independent…

9 months ago

World Leaders in Proteomics and Proteoform Biology to Convene at the 3rd International Top-Down Proteomics Symposium

The Symposium will feature scientific leaders who are creating cutting edge technologies and approaches for building the bridge from genotype…

9 months ago

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody…

9 months ago

Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change

Action Taken to Maintain Company’s Nasdaq ListingDUBLIN and BRIDGEWATER, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:…

9 months ago

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and LipodystrophyTotal Revenue $19…

9 months ago

Mars Veterinary Health Underscores Long-Term Commitment to Research & Innovation in Groundbreaking Science Impact Report

Global leader in peer-reviewed veterinary research highlights progress in advancing veterinary science and clinical excellence through inaugural science report launch…

9 months ago

Preliminary results for the year ended 31 December 2024

~ Strong commercial momentum underpins transformative financial performance ~ Strong 2024 financial performance in line with guidance Revenue growth of…

9 months ago

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect…

9 months ago